Display Settings:

Format

Send to:

Choose Destination
    Breast Cancer Res. 2010;12(3):107. Epub 2010 Jun 1.

    What do we learn from HER2-positive breast cancer genomic profiles?

    Abstract

    Patients with a tumor presenting amplification of the HER2 gene are currently proposed trastuzumab (herceptin) and this has greatly changed their outcome. However, a number of HER2-positive cancers show intrinsic or acquired resistance to trastuzumab and there are clear indications that they form a heterogeneous group of tumors. A paper in this issue of Breast Cancer Research addresses this heterogeneity at the genomic level.

    PMID:
    20519027
    [PubMed - indexed for MEDLINE]
    PMCID: PMC2917015
    Free PMC Article

      Supplemental Content

      Click here to read Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk